ATE488237T1 - Verfahren zur behandlung von abnormalem zellwachstum - Google Patents

Verfahren zur behandlung von abnormalem zellwachstum

Info

Publication number
ATE488237T1
ATE488237T1 AT06820997T AT06820997T ATE488237T1 AT E488237 T1 ATE488237 T1 AT E488237T1 AT 06820997 T AT06820997 T AT 06820997T AT 06820997 T AT06820997 T AT 06820997T AT E488237 T1 ATE488237 T1 AT E488237T1
Authority
AT
Austria
Prior art keywords
cell growth
abnormal cell
treating abnormal
treating
growth
Prior art date
Application number
AT06820997T
Other languages
English (en)
Inventor
James Gail Christensen
Yahong Zou
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE488237T1 publication Critical patent/ATE488237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06820997T 2005-12-05 2006-11-23 Verfahren zur behandlung von abnormalem zellwachstum ATE488237T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74276605P 2005-12-05 2005-12-05
US86463706P 2006-11-07 2006-11-07
PCT/IB2006/003397 WO2007066187A2 (en) 2005-12-05 2006-11-23 Method of treating abnormal cell growth

Publications (1)

Publication Number Publication Date
ATE488237T1 true ATE488237T1 (de) 2010-12-15

Family

ID=38123250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820997T ATE488237T1 (de) 2005-12-05 2006-11-23 Verfahren zur behandlung von abnormalem zellwachstum

Country Status (20)

Country Link
US (1) US7825137B2 (de)
EP (1) EP1959955B1 (de)
JP (1) JP4619346B2 (de)
KR (1) KR101026676B1 (de)
AR (1) AR056832A1 (de)
AT (1) ATE488237T1 (de)
AU (1) AU2006323027B2 (de)
BR (1) BRPI0619424B1 (de)
CA (1) CA2632286C (de)
CY (1) CY1110931T1 (de)
DE (1) DE602006018354D1 (de)
DK (1) DK1959955T3 (de)
IL (1) IL191471A (de)
NZ (1) NZ568654A (de)
PL (1) PL1959955T3 (de)
PT (1) PT1959955E (de)
RU (1) RU2384331C2 (de)
SI (1) SI1959955T1 (de)
TW (1) TWI321050B (de)
WO (1) WO2007066187A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513915A (pt) * 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
ES2424651T3 (es) * 2005-08-24 2013-10-07 Eisai R&D Management Co., Ltd. Nuevo derivado de piridina y derivado de pirimidina (3)
SI1963302T1 (sl) * 2005-12-05 2013-04-30 Pfizer Products Inc. Polimorfne oblike inhibitorja c-met/hgfr
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP2450437B1 (de) 2006-04-14 2017-05-17 Cell Signaling Technology, Inc. Gendefekte und Mutante ALK-Kinase in festen menschlichen Tumoren
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
AU2007288793B2 (en) * 2006-08-23 2012-04-19 Eisai R & D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009104520A1 (ja) * 2008-02-18 2009-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の製造方法（２）
EP2143441A1 (de) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Kombination aus einem c-MET-Antagonisten und einer Aminoheteroaryl-Verbindung zur Krebsbehandlung
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
WO2010064300A1 (ja) * 2008-12-02 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食道癌治療用組成物
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
SG182803A1 (en) 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
EP2534156A1 (de) * 2010-02-11 2012-12-19 OSI Pharmaceuticals, LLC 7-aminofuropyridinderivate
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
CN102971293A (zh) 2010-07-05 2013-03-13 默克专利有限公司 用于治疗激酶诱导的疾病的联吡啶衍生物
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
CA2829025A1 (en) * 2011-03-03 2012-09-07 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2012119690A1 (en) 2011-03-09 2012-09-13 Merck Patent Gmbh Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses
WO2013041038A1 (en) * 2011-09-21 2013-03-28 Teligene Ltd. Pyridine compounds as inhibitors of kinase
AU2013216006B2 (en) 2012-01-31 2017-06-08 Daiichi Sankyo Company, Limited Pyridone derivatives
GEP201606560B (en) 2012-03-06 2016-10-25 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
HUE037856T2 (hu) 2012-04-18 2018-09-28 Cell Signaling Technology Inc EGFR és ROS1 rákban
CN103509008A (zh) * 2012-06-22 2014-01-15 康瑟特制药公司 吡唑取代的氨基-杂芳基化合物的衍生物
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
DK2898329T3 (en) 2012-09-24 2017-07-17 Ventana Med Syst Inc PROCEDURE FOR IDENTIFYING TREATMENT RESPONSIBLE NON-SMALL CELL LUNG CANCER USING ANAPLASTIC Lymphoma Kinase (ALK) AS MARKER
KR102156398B1 (ko) * 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
EA201201654A1 (ru) * 2012-12-28 2014-06-30 Ооо "Эн.Си.Фарм" Противоопухолевое средство (варианты)
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
EA201591644A1 (ru) * 2013-03-13 2016-05-31 Ратиофарм Гмбх Лекарственная форма, содержащая кризотиниб
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6291179B2 (ja) * 2013-07-26 2018-03-14 関東化學株式会社 光学活性２級アルコールの製造方法
US20160214961A1 (en) * 2013-09-10 2016-07-28 Shilpa Medicare Limited Novel salts of crizotinib and their preparation
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EP3185866A1 (de) 2014-08-25 2017-07-05 Pfizer Inc. Kombination aus einem pd-1-antagonisten und einem alk-inhibitor zur behandlung von krebs
CN113683564A (zh) 2014-08-28 2021-11-23 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
US12066428B2 (en) * 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
PL3458053T3 (pl) 2016-05-20 2022-04-25 Biohaven Therapeutics Ltd. Stosowanie riluzolu, proleków riluzolu lub analogów riluzolu z immunoterapiami w leczeniu nowotworów
GB201616116D0 (en) * 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN108047231B (zh) * 2018-01-02 2020-02-11 江苏医药职业学院 [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
CA2216796C (en) * 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
ID30460A (id) * 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
US6498165B1 (en) * 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
JP2004500383A (ja) * 2000-02-16 2004-01-08 ニューロゲン　コーポレイション 置換アリールピラジン
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) * 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
WO2004076412A2 (en) * 2003-02-26 2004-09-10 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
CN1984651A (zh) * 2004-05-05 2007-06-20 细胞基因公司 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物
BRPI0513915A (pt) * 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
MX2007001986A (es) * 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
SI1963302T1 (sl) * 2005-12-05 2013-04-30 Pfizer Products Inc. Polimorfne oblike inhibitorja c-met/hgfr

Also Published As

Publication number Publication date
KR101026676B1 (ko) 2011-04-04
AU2006323027B2 (en) 2012-08-02
PT1959955E (pt) 2011-01-04
WO2007066187A3 (en) 2008-01-17
RU2384331C2 (ru) 2010-03-20
TW200727899A (en) 2007-08-01
KR20080072965A (ko) 2008-08-07
WO2007066187A2 (en) 2007-06-14
RU2008122471A (ru) 2009-12-10
JP2007153894A (ja) 2007-06-21
TWI321050B (en) 2010-03-01
BRPI0619424A2 (pt) 2011-10-04
IL191471A (en) 2013-03-24
NZ568654A (en) 2012-02-24
DK1959955T3 (da) 2011-02-07
IL191471A0 (en) 2009-08-03
CA2632286A1 (en) 2007-06-14
JP4619346B2 (ja) 2011-01-26
CY1110931T1 (el) 2015-06-10
AU2006323027A1 (en) 2007-06-14
EP1959955A2 (de) 2008-08-27
CA2632286C (en) 2011-11-15
US7825137B2 (en) 2010-11-02
EP1959955B1 (de) 2010-11-17
HK1126121A1 (en) 2009-08-28
US20080300273A1 (en) 2008-12-04
BRPI0619424B1 (pt) 2022-02-08
PL1959955T3 (pl) 2011-04-29
SI1959955T1 (sl) 2011-02-28
DE602006018354D1 (de) 2010-12-30
AR056832A1 (es) 2007-10-24

Similar Documents

Publication Publication Date Title
ATE488237T1 (de) Verfahren zur behandlung von abnormalem zellwachstum
EP2294183A4 (de) Mesenchymale stammzellen, zusammensetzungen und verfahren zur behandlung von herzgewebeschäden
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE494780T1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
EP1937143A4 (de) Verfahren zur beurteilung von harnstress-inkontinenz
DE602006007890D1 (de) Verfahren zur Optimierung von Kombikraftwerken/Kombiverarbeitungsanlagen
DE502006001614D1 (de) Verfahren zur herstellung von 1-alkyl-3-phenyluracilen
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
EP2049140A4 (de) Kit und verfahren zur behandlung der bandscheiben
EP2278979A4 (de) Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden
EP2039757A4 (de) Verfahren zur zell- oder gewebekultivierung
EP1948178A4 (de) Verfahren zur behandlung von vorhofflimmern mit p38-inhibitor-verbindungen
EP2046366A4 (de) Verfahren zur behandlung von altersbedingter makuladegeneration
EP2099446A4 (de) Verfahren zur behandlung von entzündlicher darmerkrankung
ATE544341T1 (de) Verfahren zur verbesserung des nematoden toleranten bzw. -resistenten pflanzenwachstums
EP2037736A4 (de) Verfahren zur behandlung von zystennierenerkrankungen
EP1948675A4 (de) Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
EP2120994A4 (de) Verfahren und zusammensetzungen zur behandlung hypoglykämischer zustände
EP1848834A4 (de) Verfahren zur behandlung von kupferhaltigen materialien
ZA200804777B (en) Method of treating abnormal cell growth
DE502005010287D1 (de) Verfahren zur hydrocyanierung
EP1960416A4 (de) Verfahren zur aufreinigung von chenodesoxycholsäure
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
EP1845971A4 (de) Verfahren zur behandlung von zellschäden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1959955

Country of ref document: EP